Identification of clinically significant nocardiae to the species level is important in patient diagnosis and treatment. A study was performed to evaluate Nocardia species identification obtained by partial 16S ribosomal DNA (rDNA) sequencing by the MicroSeq 500 system with an expanded database. The expanded portion of the database was developed from partial 5 16S rDNA sequences derived from 28 reference strains (from the American Type Culture Collection and the Japanese Collection of Microorganisms). The expanded MicroSeq 500 system was compared to (i) conventional identification obtained from a combination of growth characteristics with biochemical and drug susceptibility tests; (ii) molecular techniques involving restriction enzyme analysis (REA) of portions of the 16S rRNA and 65-kDa heat shock protein genes; and (iii) when necessary, sequencing of a 999-bp fragment of the 16S rRNA gene. An unknown isolate was identified as a particular species if the sequence obtained by partial 16S rDNA sequencing by the expanded MicroSeq 500 system was 99.0% similar to that of the reference strain. Ninety-four nocardiae representing 10 separate species were isolated from patient specimens and examined by using the three different methods. Sequencing of partial 16S rDNA by the expanded MicroSeq 500 system resulted in only 72% agreement with conventional methods for species identification and 90% agreement with the alternative molecular methods. Molecular methods for identification of Nocardia species provide more accurate and rapid results than the conventional methods using biochemical and susceptibility testing. With an expanded database, the MicroSeq 500 system for partial 16S rDNA was able to correctly identify the human pathogens N. brasiliensis, N. cyriacigeorgica, N. farcinica, N. nova, N. otitidiscaviarum, and N. veterana.
Identification of clinically significant nocardiae to the species level is important in patient diagnosis and treatment. A study was performed to evaluate Nocardia species identification obtained by partial 16S ribosomal DNA (rDNA) sequencing by the MicroSeq 500 system with an expanded database. The expanded portion of the database was developed from partial 5 16S rDNA sequences derived from 28 reference strains (from the American Type Culture Collection and the Japanese Collection of Microorganisms). The expanded MicroSeq 500 system was compared to (i) conventional identification obtained from a combination of growth characteristics with biochemical and drug susceptibility tests; (ii) molecular techniques involving restriction enzyme analysis (REA) of portions of the 16S rRNA and 65-kDa heat shock protein genes; and (iii) when necessary, sequencing of a 999-bp fragment of the 16S rRNA gene. An unknown isolate was identified as a particular species if the sequence obtained by partial 16S rDNA sequencing by the expanded MicroSeq 500 system was 99.0% similar to that of the reference strain. Ninety-four nocardiae representing 10 separate species were isolated from patient specimens and examined by using the three different methods. Sequencing of partial 16S rDNA by the expanded MicroSeq 500 system resulted in only 72% agreement with conventional methods for species identification and 90% agreement with the alternative molecular methods. Molecular methods for identification of Nocardia species provide more accurate and rapid results than the conventional methods using biochemical and susceptibility testing. With an expanded database, the MicroSeq 500 system for partial 16S rDNA was able to correctly identify the human pathogens N. brasiliensis, N. cyriacigeorgica, N. farcinica, N. nova, N. otitidiscaviarum, and N. veterana.
Nocardia species are aerobic and saprophytic actinomycetes found in the environment. Pathogenic species have been found in dust, sand, soil and swimming pools (17) . Nocardiae cause a variety of human infections including cutaneous, pulmonary, and systemic nocardiosis (17) .
The well-characterized medically significant Nocardia species include Nocardia abscessus (34) , N. asteroides (3) , N. nova (3) , N. farcinica (30) , N. brasiliensis (3) , N. pseudobrasiliensis (22, 23) , N. otitidiscaviarum (3) , and N. transvalensis (3, 32) . The species N. africana (11) , N. paucivorans (33) , and N. veterana (5, 10, 19) have been encountered as agents of pulmonary disease (3). Other newly described Nocardia species have not been studied extensively for clinical relevance and include members of the N. brevicatena complex (3) , N. beijingensis (31) , N. carnea (8) , N. crassostreae (7) , and N. vinacea (13, 15) . Members of the N. asteroides complex have been grouped according to drug susceptibility patterns (23, 29) . N. asteroides drug pattern types III and V have been determined to be N. nova and N. farcinica (27, 30) , respectively, while N. asteroides drug pattern type I has more recently been named N. abscessus and drug pattern type VI has been named N. cyriacigeorgica (21) . N. asteroides drug pattern types II and IV have not yet been named as individual species. It is difficult to distinguish between members of the N. asteroides drug groups by conventional biochemical techniques; however, PCR restriction enzyme analysis (REA), as well as nucleic acid sequencing of the 16S rRNA gene, can differentiate these species (6, 21, 23) .
Accurate identification of Nocardia species has become increasingly important as differences among species have emerged in terms of epidemiology, virulence, and antibiotic susceptibility (16) . Optimal therapeutic strategies are dependent on rapid and accurate identification of Nocardia species including members of the N. asteroides complex. Molecular methods for identification, such as PCR REA and sequencing, offer a time-saving alternative to conventional methods involving growth characteristics, colony and microscopic morphology, and biochemical and susceptibility testing. We evaluated a method of sequencing base positions 4 to 532 of 16S ribosomal DNA (rDNA), corresponding to the numbering system of Escherichia coli 16S rDNA positions (20) , by comparing the results to those obtained by conventional methods as well as alternative molecular techniques performed at the National Institutes of Health (NIH). The MicroSeq 500 system (Applied BioSystems, Foster City, Calif.) uses automated sequencing with kit-based reagents to allow analysis of 529 bases of the 16S rRNA gene (24) (partial 16S rDNA). Previous experience revealed that the MicroSeq 500 sequence library is limited to a few type strains, prompting us to develop an improved library which includes more strains of clinically significant species (4). A study was done to evaluate the accuracy of partial 16S rDNA sequencing using the MicroSeq 500 16S rDNA sequencing system with our expanded library and to compare it to other well-established conventional and molecular methods for identification of Nocardia species.
(Portions of this study were previously presented [J. L. Cloud, A. Croft, P. S. Conville 
MATERIALS AND METHODS
Bacterial isolates. Nocardiae evaluated for this study were isolates recovered from clinical specimens received by the ARUP Microbiology Laboratory. All gram-positive isolates with growth characteristics and colony morphology consistent with Nocardia were included in this 1-year study. A total of 94 nocardia isolates were acquired; only 1 isolate was accepted per patient. Reference strains (Table 1) were purchased from the American Type Culture Collection (ATCC) and the Japanese Collection of Microorganisms (JCM).
Expanded sequencing library. The biochemical characteristics of purchased strains (identified by ATCC or JCM) were verified by conventional techniques (described below). Sequences were generated using the MicroSeq 500 system (described below) and stored in a file within the MicroSeq software package. To verify the correct species assignment of the reference strains, text files of the sequences were compared to the currently unpublished Nocardia database of RIDOM (12) (www.ridom-rdna.de), created and maintained by the laboratory of one of the coauthors of this paper (D.H.).
MicroSeq 500 System. DNA was extracted from organisms in pure culture by using the PrepMan Ultra reagent (Applied BioSystems) and frozen at Ϫ20°C until used in the analysis (1 to 3 days). For PCR and sequencing, the DNA samples were thawed and previously described procedures were used (4). Sequences were analyzed using the MicroSeq software system (version 1.4.3) with the MicroSeq library version 500-0125 in conjunction with our expanded library ( Table 1) . Eleven Nocardia species, listed in Table 1 , are currently included in the MicroSeq 500-0125 library, while 9 species were added separately. For the purposes of this study, samples having 99.0 to 100% similarity to a species in the expanded MicroSeq 500 library were assigned that species designation provided that the colony morphology and growth characteristics were consistent. Organisms with less than 99.0% similarity to any species in the libraries were considered unidentified to the species level.
Establishing reporting criteria. The region from base positions 4 to 532 (corresponding to E. coli 16S rDNA positions) of the 16S rDNA were analyzed for 20 species of Nocardia (Table 1) . Sequences were aligned, and a pairwise distance matrix was calculated using the CLUSTAL W program with the "correct for multiple substitutions" and "exclude positions with gap" options turned off (25) . A Kolmogorov-Smirnov normality test was used to test the goodness of fit to a normal distribution of all pairwise distances. The Stat View version 5.0 statistical software package was used to calculate the K-S normality test, all descriptive statistical parameters, and the areas under the curve of a normal distribution (SAS Institute Inc., Cary, N.C.).
Conventional identification. Nocardia strains were phenotypically characterized by determination of lysozyme resistance, aerial hypha production, substrate decomposition (casein, tyrosine, xanthine, and hypoxanthine), drug susceptibility patterns, and other classical biochemical tests. Unless otherwise stated, all media were purchased from Midwest Medical (Salt Lake City, Utah). Well-isolated colonies grown on sheep blood agar or buffered charcoal yeast extract agar were inoculated to various test media as follows: (i) lysozyme and glycerol broths, (ii) substrate decomposition agar, and (iii) tap water agar (ARUP Reagent Lab, Salt Lake City, Utah). All media were incubated at 30°C and observed daily for 10 to 28 days. The results of the lysozyme resistance and substrate decomposition tests were interpreted as specified by the manufacturer's instructions for the use of lysozyme broth and degradation agar (Becton, Dickinson and Co., Sparks, Md.). If a particular isolate did not thrive or produce aerial hyphae at 30°C, the plates were transferred to a 37°C incubation to enhance growth and hypha production. The results with the test media were interpreted using the algorithm in Fig. 1 . Susceptibility testing was performed either by broth microdilution (2) or by disk diffusion (28) . Broth microdilution was performed only if a drug susceptibility panel was specifically requested by the physician. When no susceptibility panel was requested by the physician, drug susceptibilities were determined by nonstandardized disk diffusion methods for the sole purpose of organism identification. The drugs tested were amikacin, amoxicillin-clavulanate, ampicillin, cefotaxime, ciprofloxacin, erythromycin, imipenem, minocycline, sulfamethoxazole, and tobramycin. Interpretations were made at 24 to 48 hs. When indicated ( Fig.  1 ), additional tests were performed by previously published methods; they included starch hydrolysis (9, 18), 14-day arylsulfatase (14) , growth at 45°C (30), acetamide hydrolysis (30), acid production from rhamnose (30) , and cefamandole resistance (2) .
Alternative molecular techniques. Organisms grown on Trypticase soy agar were sent at room temperature to the Microbiology Service of the Warren G. Magnuson Clinical Center, National Institutes of Health. All procedures, including DNA extraction, amplification of a portion of the 16S rRNA gene, amplification of a portion of the hsp65 gene, REA, sequence determination, and sequence analysis were performed as previously described (6) . REA results for both amplicons from the 16S rRNA and hsp65 genes were first analyzed. If discrepant REA identifications were obtained from the two gene regions, sequencing of a 999-bp portion of the 16S rRNA gene was performed and the sequences were analyzed using a BLAST search of the GenBank database (www .ncbi.nlm.nih.gov). An isolate was assigned to a particular species if the 16S rRNA sequence of the isolate was Ն99.3% similar to the type strain of the most closely related species indicated by the BLAST search. The 99.3% similarity cutoff was arbitrarily selected based on previous experience with Nocardia species (6). The percent similarity was determined using alignments of the sequence of the isolate in question (Megalign; DNASTAR, Madison, Wis.) with the sequence of the type strain determined in the NIH laboratory or with GenBank sequences determined to be reliable. Isolates were designated "Nocardia species" if the percent similarity to the type strain of the closest species was Ͻ99.3% or if the BLAST search indicated closest similarity to an unnamed species.
RESULTS
The sequences generated for the reference strains by the MicroSeq 500 system for use in the expanded database showed 100% similarity to the sequences for these strains in the unpublished Nocardia database of RIDOM. A total of 94 presumptive Nocardia spp. were isolated and/or submitted for identification from a variety of specimen types. N. africana (11) and N. veterana (10) are two recently described species that are phylogenetically related and phenotypically similar to each other (5). Reference strains of N. africana (ATCC BAA-280 T ) and N. veterana (JCM 11307 T ) were sequenced using the expanded MicroSeq 500 system for comparison with four isolates with sequence similarity to N. africana and N. veterana. Partial 16S rDNA sequences from three of the four isolates showed 100% similarity to the type strain of N. veterana when the expanded MicroSeq 500 system was used.
The remaining isolate was also identified as N. veterana with a similarity score of 99.6%. Alternative molecular techniques identified three of these isolates as N. veterana and one as belonging to the N. africana-N. veterana group. Using the expanded MicroSeq 500 system, all of the N. veterana clinical isolates were 99.0% similar to the N. nova type strain (ATCC 33726). None of the clinical isolates matched the N. africana type strain. The reference strain of N. nova (ATCC 33727) showed 100% similarity to N. veterana by the expanded MicroSeq 500 system, suggesting that this strain is actually N. veterana and was deposited with ATCC before N. veterana was described.
Three isolates showed 100% similarity by the expanded MicroSeq 500 system to the sequence of the type strain of N. beijingensis. Another isolate was 99.2% similar to N. beijingensis. Identification of the four isolates by the expanded MicroSeq 500 system was in agreement with identification by alternative molecular methods, but they were identified as N. asteroides by conventional methods.
Eight isolates were identified by the expanded MicroSeq 500 (Fig. 2) on the basis of partial 16S rDNA sequences. Roth et al. (21) evaluated the phylogenetic relationship by using full 16S rDNA sequences and demonstrated that N. beijingensis is not closely related to N. abscessus, suggesting further sequencing beyond the first 500 bases may be necessary for accurate delineation of the relationship between these species. Of eight isolates identified as N. abscessus by the expanded MicroSeq 500 system, four showed 100% similarity to the N. abscessus type strain, two showed 99.8% similarity to the type strain, and two were 99.6% similar to the type strain. Sequencing 999 bp of the 16S rRNA gene assigned N. beijingensis to half of this group and N. abscessus to the remaining half for 50% agreement with the expanded MicroSeq 500 system. Conventional methods named five of the isolates as N. asteroides and the remaining three as unassigned species.
Fourteen isolates were identified by the expanded MicroSeq 500 system as members of the Nocardia genus but were not assigned a definitive species because of too much divergence in sequence similarity. One isolate assigned a species designation by the alternative methods as N. beijingensis (99.3% similarity to the N. beijingensis type strain) had a similarity index by the expanded MicroSeq 500 system which was below the arbitrary cutoff. One isolate was identified as N. pseudobrasilisensis by REA; subsequent 16S rRNA gene sequencing of the 999-bp region to resolve this discrepancy showed this isolate to be unrelated to any described Nocardia species.
The mean pairwise distance of 20 unique partial rDNA nocardiae sequences was 3.2%, the standard deviation was 1.2%, the minimum was 0.2%, and the maximum distance was 6.6%. The result of a K-S normality test was not significant (i.e., P Ͻ 0.05), suggesting that the pairwise distances are normally distributed. Our choice of a reporting criterion of Ն99.0% similarity (1.0% divergence) for a "distinct species" correlates to a statistical error probability of 3.0% (i.e., in only 3.0% of cases do two distinct species exhibit a similarity value greater than or equal to 99.0%).
DISCUSSION
The primary aim of the present study was to assess the reliability of an expanded database for the MicroSeq 500 se-FIG. 2. Phylogenetic tree relating the partial 16S rDNA sequences included in the expanded MicroSeq 500 library. Two designated outgroups, Escherichia coli (ATCC 11775 T ) and Rhodococcus ruber (ATCC 14898 T ), are included for reference of relatedness. The algorithm used to construct the tree is the unweighted pair group method using averages (UPGMA). Reference strain numbers ending in T are type strains.
quencing system used to identify Nocardia species from clinical isolates. When identifying Nocardia species using the expanded MicroSeq 500 system, accuracy was verified when similar results were obtained by using PCR REA of two separate gene targets and 999-bp 16S rDNA sequencing with a BLAST search of the GenBank public database (1) and subsequent independent alignments when necessary. Throughout the study, GenBank was used with caution since 16S rDNA sequences of many Nocardia species are not included in public databases, taxonomic changes are not often applied to public databases, and many faulty entries are found in publicly accessible databases (26) .
Conventional methods for identification of Nocardia species produced more isolates that could not be assigned to a particular species (23%) than did the expanded MicroSeq 500 system (14%) or alternative molecular methods (15%). There were 10 discrepancies between the expanded MicroSeq 500 system and the alternative molecular methods, probably due to the number of bases examined by each technique, the use of different databases, and different interpretive strategies. Of the 10 discrepancies, 4 were identified as N. abscessus by the expanded MicroSeq 500 system but called N. beijingensis by the alternative molecular techniques. These discrepancies are a result of sequence differences in the 16S rRNA gene region not examined by the expanded MicroSeq 500 system. While all four isolates showed significant similarity to the N. abscessus type strain (ATCC BAA-290 T ) in the first 500-bp region (99.8 to 100% similarity with 0 to 1 base difference), sequence analysis of the 999-bp region showed these isolates to be only 98.3 to 98.4% similar (14 to 15 base differences) to the N. abscessus type strain. Sequence analysis of the 999-bp region showed 99.3 to 99.4% similarity to the N. beijingensis type strain with 5 to 6 base differences. Therefore, any isolate identified as N. abscessus by the expanded MicroSeq 500 system should be further analyzed using a larger region of the 16S rRNA gene to provide a more definitive identification. Because N. beijingensis has not yet been implicated as a human pathogen, more studies are needed to determine if isolates identified as N. beijingensis in this study are actually members of this species and to further define N. beijingensis-like clinical isolates whose sequences are similar but not 100% identical to the type strain.
As with N. beijingensis, N. vinacea has not yet been implicated as a human pathogen. Further studies are necessary to determine if the isolates identified as N. vinacea in this study are actually representatives of this species and to determine the possible role of this species in human disease.
Three of the discrepancies involved isolates identified as N. asteroides drug pattern IV by the expanded MicroSeq 500 system but unidentified to the species level by the alternative molecular methods. Sequence analysis of the 999-bp region of one of these isolates showed 99.1% similarity to the N. asteroides drug pattern IV reference strain. By the alternative molecular methods, two isolates showed Յ98.2% similarity to the N. asteroides drug pattern IV reference strain; as noted above for N. abscessus, most of the sequence divergence for these isolates occurred in the extended gene region not examined by the MicroSeq 500 system.
The two remaining discrepancies were due to similarity scores achieved with the expanded MicroSeq 500 system of less than 99.0%. Both had the closest match as being the assigned species of the alternative molecular methods (N. beijingensis and N. pseudobrasiliensis). The isolate identified as N. beijingensis by alternative molecular techniques showed 99.3% similarity to the N. beijingensis type strain, with all base discrepancies occurring within the first 500 bases. The misidentification of N. pseudobrasiliensis by REA indicates a potential pitfall in using REA alone for the identification of this species, and further studies need to be performed to optimize N. pseudobrasiliensis identification using this method.
Nocardia isolates that could not be definitively identified to the species level are probably unidentifiable because a large number of Nocardia species still await recognition as new species. We expect this percentage to become smaller as new taxonomic descriptions lead to valid species. From recent reports (21), it is suggested that N. asteroides drug pattern type II has a partial 16S rDNA sequence identical to that of a clinical isolate in this study that was 98.8% similar to N. carnea ( Table  2 ). The strain probably represents a new species and requires further genetic and phenotypic evaluation to become a valid species. With proper database management, one can add sequences of new species to a database as they become validly described and made available for studies.
It is interesting that the sequence of the N. asteroides type strain did not match any of the clinical isolates. Most (53%) of the N. asteroides complex isolates gave perfect matches to N. cyriacigeorgica, while the remaining isolates were split among N. asteroides drug group IV and N. abscessus.
Of 81 species assigned, 21 demonstrated greater than 99.0% but less than 100% similarity to the most closely related species when tested by the expanded MicroSeq 500 system. These could be variants of the same species or distinct but closely related species, or could represent an error in base sequence analysis. For the present study, the chance of incorrect base sequence analysis was low, since we used sequence analysis by two independent individuals and any sequence requiring more than 10 edits was more closely evaluated and repeated, if necessary.
The question of how similar a strain must be to a reference strain before a species should be assigned by the expanded MicroSeq 500 system was addressed via statistics, but the assignment is arbitrary and still requires confirmation by further molecular analysis including DNA-DNA hybridization. Based on our experience with Mycobacterium species, we established reporting criteria for partial 16S rDNA sequence analysis to report a species if it is greater than 99.0% similar to the reference strain in the database. Calculations for reporting a threshold will vary among genera due to the varying diversity exhibited in each genus. As our database grows, with the addition of new species and sequevars of the same species, calculation of the reporting threshold will change. Ideally, all Nocardia species possible should be included in the calculation of reporting criteria.
The most important component for successful sequencing in the identification of bacterial isolates is an accurate and complete database. In the era of 16S rDNA sequencing, we continue to find more changes being made to Nocardia taxonomy as well as numerous descriptions of new species. A large collaborative effort to establish a 16S rDNA database would contribute significantly to the success of clinical laboratories in bringing 16S rDNA sequencing into their bacterial identifica- Once an improved database was developed, the incorporation of the expanded MicroSeq 500 system into our identification algorithm brought more accuracy to the identification of Nocardia species while significantly decreasing the turnaround time from that of conventional identification. The average time to identify Nocardia isolates in culture has dropped from 2-3 weeks to 1-3 days when expanded MicroSeq 500 sequencing is employed.
This study shows that the expanded MicroSeq 500 system is able to identify six human pathogens (N. brasiliensis, N. cyriacigeorgica, N. farcinica, N. nova, N. otitidiscaviarum, and N. veterana). N. abscessus and N. asteroides drug pattern IV are not distinctly identified but are easily differentiated from other species, and for these species extended regions of the 16S rDNA gene can be analyzed to give a more accurate species assignment. The ability of the system to identify the human pathogens N. africana, N. paucivorans, and N. pseudobrasiliensis has not been determined.
